Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma ...
Transcarent acquires Accolade for $621M in cash deal led by CEO Glen Tullman, combining health navigation platforms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback